This company listing is no longer active
A8C1 Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Abcam plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.70 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$12.20 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | -8.67% |
| 1 Year Change | -14.85% |
| 3 Year Change | -18.26% |
| 5 Year Change | 0.74% |
| Change since IPO | 268.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| A8C1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -1.5% |
| 1Y | -14.9% | -19.9% | 0.9% |
Return vs Industry: A8C1 underperformed the German Biotechs industry which returned 7.6% over the past year.
Return vs Market: A8C1 underperformed the German Market which returned -13% over the past year.
Price Volatility
| A8C1 volatility | |
|---|---|
| A8C1 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: A8C1 has not had significant price volatility in the past 3 months.
Volatility Over Time: A8C1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,682 | Alan Hirzel | www.abcam.com |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
Abcam plc Fundamentals Summary
| A8C1 fundamental statistics | |
|---|---|
| Market cap | €3.47b |
| Earnings (TTM) | €8.31m |
| Revenue (TTM) | €398.69m |
417.8x
P/E Ratio8.7x
P/S RatioIs A8C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A8C1 income statement (TTM) | |
|---|---|
| Revenue | UK£350.40m |
| Cost of Revenue | UK£89.90m |
| Gross Profit | UK£260.50m |
| Other Expenses | UK£253.20m |
| Earnings | UK£7.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 74.34% |
| Net Profit Margin | 2.08% |
| Debt/Equity Ratio | 16.4% |
How did A8C1 perform over the long term?
See historical performance and comparison